Core Viewpoint - Trinity Biotech plc has received a notice from Nasdaq regarding non-compliance with the minimum bid price requirement for its American Depositary Shares (ADSs), which must be at least $1.00 per share for 30 consecutive business days [1][2]. Company Compliance Status - The notice does not immediately affect the trading status of the Company's ADSs, which will continue to be listed on the Nasdaq Global Select Market under the symbol "TRIB" [2]. - The Company has a 180-calendar day period, until August 10, 2026, to regain compliance with the minimum bid price requirement [2]. - To regain compliance, the closing bid price of the Company's ADSs must meet or exceed $1.00 for at least ten consecutive business days during this grace period [2]. Management's Response - The Company's management is actively monitoring the bid price of its ADSs and intends to cure the deficiency within the grace period [3]. - Various options are being evaluated by management to regain compliance and maintain the continued listing of the ADSs [3]. Company Overview - Trinity Biotech is a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors [5]. - The Company develops, acquires, manufactures, and markets diagnostic systems for point-of-care and clinical laboratory segments, and has recently entered the wearable biosensor industry through the acquisition of Waveform Technologies Inc. [5]. - Products include systems to detect infectious diseases and quantify Haemoglobin A1c levels, with sales occurring directly in the U.S. and through international distributors in over 75 countries [6].

Core Insights - Trinity Biotech plc has announced a strategic collaboration with a leading bioinformatics company to enhance the analysis of clinical trial data for its EpiCapture test, a PCR-based epigenetic liquid biopsy for monitoring prostate cancer progression [1][3] - The EpiCapture test offers a non-invasive method to detect DNA methylation patterns associated with high-grade prostate cancer, aiming to improve patient care by reducing unnecessary invasive procedures [2][5] - Prostate cancer represents a significant clinical and economic burden, with approximately 1 in 8 men diagnosed in the U.S. and annual costs for diagnosis and treatment exceeding $10 billion [4] Company Overview - Trinity Biotech is a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors [9] - The company develops and markets diagnostic systems for point-of-care and clinical laboratory segments, recently entering the wearable biosensor market through the acquisition of Waveform Technologies Inc. [9] - Trinity Biotech's products are utilized to detect infectious diseases and quantify various chemistry parameters in blood samples, with a distribution network spanning over 75 countries [9] Clinical Development - The collaboration aims to support the late-stage development of the EpiCapture test, preparing it for regulatory approval and commercialization [3][7] - A study published in The Journal of Clinical Oncology – Precision Oncology indicated that EpiCapture accurately predicted all high-grade cancers when used with the PSA test, highlighting its potential to enhance clinical decision-making [6]

Core Viewpoint - iRhythm Technologies, Inc. will release its financial results for Q2 2025 on July 31, 2025, followed by a conference call to discuss the results [1] Company Overview - iRhythm Technologies is a leading digital health care company focused on creating solutions that detect, predict, and prevent disease [3] - The company utilizes wearable biosensors and cloud-based data analytics combined with proprietary algorithms to transform data from millions of heartbeats into clinically actionable information [3] - iRhythm aims to enhance patient care by providing better data, insights, and health outcomes [3] Conference Call Details - The conference call will begin at 1:30 p.m. PT / 4:30 p.m. ET on the same day as the financial results release [1] - Interested parties can access a live and archived webcast of the conference call on the company's investor website [2]